Bristol-Myers Squibb (BMY) Price & Analysis

Compare

11,504 Followers

BMY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$39.35 - $63.33

Previous CloseN/A

Volume3.98M

Average Volume (3M)13.70M

Market Cap

$99.03B

Enterprise Value$184.85B

Total Cash (Recent Filing)$11.78B

Total Debt (Recent Filing)$51.24B

Price to Earnings (P/E)18.3

Beta0.18

Next Earnings

Jul 31, 2025

EPS Estimate

1.61

Last Dividend Ex-Date

Apr 04, 2025

Dividend Yield6.04%

Share Statistics

EPS (TTM)1.80

Shares Outstanding2,035,080,800

10 Day Avg. Volume11,062,717

30 Day Avg. Volume13,697,319

Financial Highlights & Ratios

PEG Ratio-4.24

Price to Book (P/B)4.93

Price to Sales (P/S)0.00

P/FCF Ratio12.83

Enterprise Value/Market Cap1.87

Enterprise Value/Revenue0.97

Enterprise Value/Gross Profit5.88

Enterprise Value/Ebitda6.26

Forecast

1Y Price Target

$59.53

Price Target Upside26.04% Upside

Rating ConsensusHold

Number of Analyst Covering20

Bristol-Myers Squibb News

See All News >

Bulls Say, Bears Say

Bulls Say

Business DevelopmentBristol Myers announced entry into a partnership with BioNTech to co-develop and co-commercialize BioNTech’s PD-L1xVEGF bispecific antibody, BNT327, across multiple solid tumor types.

Financial PerformanceCobenfy TRx increased +16.2% WoW, normalizing following the holiday week, reaching 1,933 TRx.

Product DevelopmentBNT327 demonstrated promising median and 12-month landmark OS signals relative to benchmark studies, along with low treatment discontinuation rates due to AEs.

Bears Say

Clinical RiskThe deal carries clinical risk of achieving clinically meaningful overall survival benefit.

Market CompetitionThe development space is crowded, including several PD-L1 and PD-1 VEGF bispecifics in development.

Revenue EstimatesCobenfy scripts are tracking behind what is needed to beat Visible Alpha consensus estimates for 2Q25 revenue.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.05% Insiders

22.60% Mutual Funds

17.09% Other Institutional Investors

34.77% Public Companies and Individual Investors

Detailed Ownership Overview >

BMY FAQ

What was Bristol-Myers Squibb’s price range in the past 12 months?

Bristol-Myers Squibb lowest stock price was $39.35 and its highest was $63.33 in the past 12 months.

What is Bristol-Myers Squibb’s market cap?

Bristol-Myers Squibb’s market cap is $99.03B.

When is Bristol-Myers Squibb’s upcoming earnings report date?

Bristol-Myers Squibb’s upcoming earnings report date is Jul 31, 2025 which is in 43 days.

How were Bristol-Myers Squibb’s earnings last quarter?

Bristol-Myers Squibb released its earnings results on Apr 24, 2025. The company reported $1.8 earnings per share for the quarter, beating the consensus estimate of $1.495 by $0.305.

Is Bristol-Myers Squibb overvalued?

According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bristol-Myers Squibb pay dividends?

Bristol-Myers Squibb pays a Notavailable dividend of $0.62 which represents an annual dividend yield of 6.04%. See more information on Bristol-Myers Squibb dividends here

What is Bristol-Myers Squibb’s EPS estimate?

Bristol-Myers Squibb’s EPS estimate is 1.61.

How many shares outstanding does Bristol-Myers Squibb have?

Bristol-Myers Squibb has 2,035,080,800 shares outstanding.

What happened to Bristol-Myers Squibb’s price movement after its last earnings report?

Bristol-Myers Squibb reported an EPS of $1.8 in its last earnings report, beating expectations of $1.495. Following the earnings report the stock price went up 0.33%.

Which hedge fund is a major shareholder of Bristol-Myers Squibb?

Currently, no hedge funds are holding shares in BMY

Bristol-Myers Squibb Stock Smart Score

Neutral

Fundamentals

Return on Equity

31.99%

Trailing 12-Months

Asset Growth

-6.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bristol-Myers Squibb

Bristol-Myers Squibb (BMY) is a global biopharmaceutical company headquartered in New York City. It is dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company focuses on therapeutic areas such as oncology, cardiovascular, immunoscience, and fibrosis. Key products include Opdivo and Yervoy in oncology, Eliquis for cardiovascular conditions, and Orencia for immunoscience.

BMY Company Deck

BMY Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call showed strong financial performance and successful product launches, which were slightly overshadowed by disappointing clinical trial results and challenges related to the regulatory environment and Medicare Part D redesign.Read More>

BMY Revenue Breakdown

70.61% U.S.

27.33% International

2.06% Other

BMY Stock 12 Month Forecast

Average Price Target

$59.53

▲(26.04%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","116":"$116","55.25":"$55.3","75.5":"$75.5","95.75":"$95.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$59.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,55.25,75.5,95.75,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.79,53.88307692307692,58.97615384615385,64.06923076923077,69.16230769230769,74.25538461538461,79.34846153846154,84.44153846153847,89.53461538461539,94.62769230769231,99.72076923076924,104.81384615384616,109.90692307692308,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.79,49.61615384615384,50.44230769230769,51.26846153846154,52.09461538461539,52.92076923076923,53.746923076923075,54.573076923076925,55.39923076923077,56.22538461538461,57.05153846153846,57.87769230769231,58.70384615384616,{"y":59.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.79,47.80615384615385,46.82230769230769,45.83846153846154,44.854615384615386,43.87076923076923,42.886923076923075,41.903076923076924,40.919230769230765,39.93538461538461,38.95153846153846,37.9676923076923,36.98384615384615,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.16,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.36,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.61,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":48.33,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":51.19,"date":1727740800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":53.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.61,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >